247 related articles for article (PubMed ID: 32357822)
1. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
[TBL] [Abstract][Full Text] [Related]
3. Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1.
Qi Y; Yao X; Du X
IUBMB Life; 2020 Mar; 72(3):452-464. PubMed ID: 31651086
[TBL] [Abstract][Full Text] [Related]
4. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
5. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
7. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-27a-3p inhibits cell viability and migration through down-regulating DUSP16 in hepatocellular carcinoma.
Li JM; Zhou J; Xu Z; Huang HJ; Chen MJ; Ji JS
J Cell Biochem; 2018 Jul; 119(7):5143-5152. PubMed ID: 29143999
[TBL] [Abstract][Full Text] [Related]
9. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.
Yang Y; Yang Z; Zhang R; Jia C; Mao R; Mahati S; Zhang Y; Wu G; Sun YN; Jia XY; Aimudula A; Zhang H; Bao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34096570
[TBL] [Abstract][Full Text] [Related]
10. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.
He H; Tian W; Chen H; Deng Y
Mol Med Rep; 2016 Feb; 13(2):1923-9. PubMed ID: 26718267
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.
Li R; Xu T; Wang H; Wu N; Liu F; Jia X; Mi J; Lv J; Gao H
Biochem Biophys Res Commun; 2019 Nov; 519(2):358-365. PubMed ID: 31519321
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5.
Zhang Z; Han Y; Sun G; Liu X; Jia X; Yu X
Cell Mol Biol Lett; 2019; 24():13. PubMed ID: 30805015
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.
Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866
[TBL] [Abstract][Full Text] [Related]
15. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
16. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
17. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
18. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
Guo XL; Wang HB; Yong JK; Zhong J; Li QH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
[TBL] [Abstract][Full Text] [Related]
19. Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma.
Tang H; Zhang J; Yu Z; Ye L; Li K; Ding F; Feng X; Meng W
Technol Cancer Res Treat; 2017 Dec; 16(6):1136-1149. PubMed ID: 29332449
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
